Stabilized preparations for use in metered dose inhalers
AssigneeNovartis Pharma AG
InventorsJeffry G. Weers, Ernest G. Schutt, Luis Dellamary, Thomas E. Tarara, Alexey Kabalnov
Life of this patent
Estimating the term…
Loading patent…
AssigneeNovartis Pharma AG
InventorsJeffry G. Weers, Ernest G. Schutt, Luis Dellamary, Thomas E. Tarara, Alexey Kabalnov
Estimating the term…
Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.
A stable respiratory dispersion for the pulmonary delivery of one or more bioactive agents comprising a suspension medium having dispersed therein a plurality of perforated microstructures comprising at least one bioactive agent wherein said suspension medium comprises at least one propellant and substantially permeates said perforated microstructures.
A system for the pulmonary administration of a bioactive agent comprising:
A method for forming a stabilized respiratory dispersion comprising the steps of:
A method for the pulmonary delivery of one or more bioactive agents comprising the steps of:
A method of increasing the effective pulmonary deposition of a bioactive agent using a metered dose inhaler comprising the steps of:
A method for stabilizing a dispersion by reducing attractive van der Waals forces comprising the steps of:
A respiratory dispersion for the pulmonary delivery of one or more bioactive agents comprising a suspension medium having dispersed therein a plurality of microparticles comprising greater than about 20% w/w surfactant and at least one bioactive agent wherein said suspension medium comprises at least one propellant.
Dependencies are inferred from the claim text.